Shahid Zainab, Packard Elizabeth, Groff Andrew, Jain Rohit
Lake Erie College of Osteopathic Medicine, Erie, Pennsylvania, USA.
Department of Internal Medicine, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA.
BMJ Case Rep. 2019 Aug 28;12(8):e231185. doi: 10.1136/bcr-2019-231185.
Eluxadoline is a novel medication that was approved in the USA in 2015 for the treatment of diarrhoea-predominant irritable bowel syndrome. Due to its unique mechanism of action as both an opioid agonist and antagonist, it has been placed as a schedule IV controlled substance. Since its approval, there have been several cases of eluxadoline-induced pancreatitis reported in the literature. The majority of patients who presented with eluxadoline-induced pancreatitis were reported to have had a prior cholecystectomy. Due to this, the Food and Drug Administration released a warning in 2017 that eluxadoline should no longer be used in patients who do not have a gall bladder. We present a rare case of an adult man without prior cholecystectomy who presented with severe mid-epigastric pain and was found to have eluxadoline-induced pancreatitis.
埃卢多啉是一种新型药物，于2015年在美国获批用于治疗腹泻型肠易激综合征。由于其作为阿片类激动剂和拮抗剂的独特作用机制，它被列为IV类管制物质。自获批以来，文献中已报道了几例埃卢多啉诱发胰腺炎的病例。据报道，大多数出现埃卢多啉诱发胰腺炎的患者此前都做过胆囊切除术。因此，美国食品药品监督管理局在2017年发布了一项警告，即没有胆囊的患者不应再使用埃卢多啉。我们报告了一例罕见病例，一名成年男性此前未做过胆囊切除术，出现严重上腹部中部疼痛，被诊断为埃卢多啉诱发的胰腺炎。
